Last reviewed · How we verify
MB-6
At a glance
| Generic name | MB-6 |
|---|---|
| Also known as | Folinic acid; Fluorouracil ; Oxaliplatin |
| Sponsor | Microbio Co Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Trial of MB-6 for Reduction of Neutropenia Induced by Chemotherapy in Patients With Stage III Colorectal Cancer.
- Molecular Content of Peri-implant Sulcus During Wound Healing and Osseointegration Following Drilling and Piezosurgery (NA)
- Uniform Multidrug Therapy Regimen for Leprosy Patients (PHASE4)
- A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer (FDA IND 103675) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MB-6 CI brief — competitive landscape report
- MB-6 updates RSS · CI watch RSS
- Microbio Co Ltd portfolio CI